This variant, which is comparable to our CTMΔ12EC, has subsequently been used by Liu and colleagues to enhance CAR T cell therapy with promising effects on human xenograft tumours in mice [22] and has recently been combined with anti-CD19 CAR T cells for the treatment of large B-cell lymphoma in a limited number of patients. This evidence concerns the gene CD19 and neoplasm.